Abstract
Background The predictive power of several novel biological markers for treatment response to immune checkpoint inhibitors (ICI) is still not satisfactory for the majority of patients with cancer. It should be the goal to identify easy available blood markers to predict early treatment response to ICI for the clinically highly relevant large number of metastatic cancer patients. The current interim analysis of patients of the ST-ICI cohort therefore focuses on the development and validation of a liquid immune profile-based signature to predict response of metastatic cancer patients to ICI targeting the programmed cell death protein 1 (PD-1)/PD-L1 axis.
Methods A total number of 104 patients were prospectively enrolled. 54 immune cell subsets were prospectively analyzed in 89 patients’ peripheral blood by multicolor flow cytometry before the second administration of the ICI. Patients were randomly allocated to a training (n=56) and a validation cohort (n=33). Univariate Cox proportional hazards regression analysis and LASSO Cox model were used to create a predictive immune signature.
Results 89/104 of the cancer patients provided whole blood samples. The identified liquid immune profile-based signature (LIPS) is based on five immune cell subtypes: CD14high monocytes, CD8+/PD-1+ T cells, plasmacytoid dendritic cells (pDCs), neutrophils, and CD56+/CD16+ natural killer (NK)T cells. The signature found achieved a high accuracy (C-index 0.74 vs 0.71) for predicting overall survival (OS) benefit in both, the training and validation cohort. In both cohorts, the low-risk group had significantly longer OS than the high-risk group (HR 0.26, 95% CI: 0.12-0.56, p=0.00025; HR 0.30, 95% CI: 0.10 -0.91, p=0.024, respectively). Regarding the whole cohort, LIPS also predicted progression-free survival (PFS). Clinicopathological features with the exception of brain metastases didn’t affect the found LIPS, for both, OS and PFS.
Conclusion Our study highlights the potential predictive value of LIPS based on easy available blood markers for immunotherapeutic benefit of metastatic cancer patients.
Trial registration Prospectively registered in ClinicalTrials.gov (NCT03453892) on January 24, 2018.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03453892
Funding Statement
There was no external funding for this trial. The study was supported by the Department of Radiation Oncology, University Hospital Erlangen,University of Erlangen Nuremberg, Erlangen, Germany and partly supported by the BMBF (GREWIS alpha, 02NUK050E).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol, any amendments, and informed consent forms were approved by the institutional review boards/independent ethics committees (number: 2_17 B). The study was performed in accordance with the Declaration of Helsinki. All patients gave written informed consent before enrolment that comprised a data privacy clause for data collection and analysis for research purpose.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-Mails of the authors: Jian-Guo Zhou: jianguo.zhou{at}fau.de
Anna-Jasmina Donaubauer: Anna-Jasmina.Donaubauer{at}uk-erlangen.de
Benjamin Frey: Benjamin.Frey{at}uk-erlangen.de
Ina Becker: Ina.Becker{at}uk-erlangen.de
Sandra Rutzner: sandra.rutzner{at}uk-erlangen.de
Markus Eckstein: markus.eckstein{at}uk-erlangen.de
Roger Sun: ROGER.SUN{at}gustaveroussy.fr
Hu Ma: mahuab{at}163.com
Philipp Schubert: Philipp.Schubert{at}uk-erlangen.de
Claudia Schweizer: Claudia.Schweizer{at}uk-erlangen.de
Rainer Fietkau: Rainer.Fietkau{at}uk-erlangen.de
Eric Deutsch: Eric.DEUTSCH{at}gustaveroussy.fr
Udo S. Gaipl: udo.gaipl{at}uk-erlangen.de
Markus Hecht: markus.hecht{at}uk-erlangen.de
revised this MS.
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Abbreviations
- AUC
- The area under the ROC curve
- CI
- Confidence interval
- C-index
- Concordance index
- CTLA-4
- Cytotoxic T lymphocyte antigen-4
- ECOG
- Eastern Cooperative Oncology Group
- HNSCC
- Head and neck squamous cell carcinoma
- HR
- Hazard ratios
- ICI
- Immune checkpoint inhibitors
- IPT
- immunophenotyping
- LASSO
- Least absolute shrinkage and selection operator
- LIPS
- liquid immune profile-based signature
- NE
- Not estimate
- NK cells
- Natural killer cells
- NKT cells
- Natural killer T cells
- NSCLC
- Non-small cell lung cancer
- OS
- Overall survival
- PBMCs
- Peripheral blood mononuclear cells
- PD-1
- Programmed cell death protein 1
- pDCs
- Plasmacytoid Dendritic Cells
- PD-L1
- Programmed cell death ligand 1
- PFS
- Progression free survival
- RECIST
- Response Evaluation Criteria in Solid Tumors
- ROC
- Receiver operating characteristic
- TMB
- Tumor mutational burden
- Tregs
- Regulatory T Cells
